This is the world's first male contraceptive implant: it lasts two years and is injected in less than 10 minutes.
A group of American researchers has unveiled the world's first male contraceptive implant, which has already passed clinical trials with promising results.
It is an implantable, non-hormonal contraceptive known as Adam, which consists of a water-soluble hydrogel that is implanted in the spermatic ducts, preventing sperm from mixing with semen.
The hydrogel is designed to break down in the body after a set period of time, restoring fertility, which, according to Contraline, the American company behind the product, makes it a reversible alternative to condoms and vasectomies.
In the first phase of its clinical trial, Contraline found that ADAM could successfully block sperm release for 24 months, with no sperm detected in the semen of the two participants who had reached this point in the trial. The company adds that no serious adverse effects have been reported so far.
Alexander Pastuszak, Contraline's medical director, told the Mirror : "Our goal was to create a two-year male contraceptive option that directly addresses consumer needs."
The 25 participants in the clinical trial were enrolled at different times, and more results are expected to be published soon. The implant is inserted through a minimally invasive procedure that takes ten minutes and requires local anesthesia, so the patient remains awake.
The Adam study was presented at the American Urological Association meeting on April 26. The contraceptive company announced it has received full regulatory approval to begin its Phase 2 clinical trial in Australia, which is expected to begin in the third quarter of 2025.
Contraline describes this approval as a "major milestone in the development of long-acting, reversible male contraceptives , paving the way for accelerated progress and a global push toward much-needed innovation in reproductive health."
20minutos
